Blood Cancer Drugs Market Worth $55.6 Billion by 2025 | CAGR: 11.1%
                     Blood Cancer Drugs Market
Set to Exceed $55.6 Billion by 2025 | CAGR: 11.1%
“Blood Cancer Drugs Market [By Blood Cancer Type 
(Leukemia (Acute Myeloid Leukemia, Chronic Myeloid 
Leukemia, Acute Lymphoblastic Leukemia, Chronic 
Lymphocytic Leukemia), Lymphoma (Hodgkin Lymphoma, 
Non-Hodgkin Lymphoma (B-Cell Lymphoma, T-Cell 
Lymphoma)), and Myeloma; By Drugs (Rituaxan/Mabthera 
(Rituximab), Gleevac/Glivec (Imatinib), Revlimid 
(Lenalidomide), Velcade (Bortezomib), Tasigna (Nilotinib), 
Pomalyst (Pomalidomide), Vidaza (Azacitidine), Kyprolis 
(Carfilzomib), Adcetris (Brentuximab Vedotin), and Others); 
By Treatment Approaches (Chemotherapeutic, 
mAbs/Targeted Therapies, and Immunotherapeutic); By 
Region]: Market Size & Forecast, 2017 – 2025”
Blood Cancer Drugs Market Estimate & Forecast to 2025
The global blood cancer drugs market is anticipated to reach USD 55.6 billion by 2025 according to a new 
report published by Polaris Market Research.
The demand for blood cancer drug is primarily driven by growing death incidences by blood cancer, and 
continuous innovation for developing novel treatments with the help of several ongoing clinical trials. 
Moreover, increasing research and development of biological and targeted therapies as treatment will 
spur the blood cancer drugs market during the upcoming period. However, the high price of drugs and the 
stringent government policies will limit the growth of blood cancer drugs market during the forecast period.
The global blood cancer drugs market is segmented into blood cancer type, drugs and treatment 
approaches. On the basis of blood cancer type, the global blood cancer drugs market is segmented into 
leukemia, lymphoma and myeloma. The lymphoma segment is expected to drive the majority market of 
blood cancer drugs followed by leukemia. The global market of this segment is primarily driven by the 
increasing prevalence of lymphoma, and presence of effective treatments in the market. On the basis of 
drugs, the global blood cancer drugs market is further categorized into Rituaxan/Mabthera (Rituximab), 
Gleevac/Glivec (Imatinib), Revlimid (Lenalidomide), Velcade (Bortezomib), Tasigna (Nilotinib), Pomalyst 
(Pomalidomide), Vidaza (Azacitidine), Kyprolis (Carfilzomib), Adcetris (Brentuximab Vedotin), and Others. 
This continuous innovation for treating various sub-types of blood cancers has led to the development of 
novel types of treatments.
Copyright © Polaris Market Research & Consulting LLP 2018. All Rights Reserved 2
Blood Cancer Drugs Market Scope
By Blood Cancer Type  By Drugs By Treatment By Region Report Attributes
Approaches
 Lymphoma  Rituaxan/Mabthera  Chemotherapeutic  North America  Historic year: 2015-2016
 Gleevac/Glivec  mAbs/Targeted  Europe  Base year: 2017
 Revlimid Therapies  Asia Pacific  Forecast Year: 2017-2025
 Velcade  Immunotherapeutic  Latin America Middle East  Revenue ((USD Billion)
 Tasigna & Africa 
 Pomalyst 
 Vidaza 
 Kyprolis 
 Adcetris 
 Others
Request for sample
Copyright © Polaris Market Research & Consulting LLP 2018. All Rights Reserved 3
Blood Cancer Drugs Market Estimate & Forecast to 2025
On the basis of treatment approaches the global blood cancer drugs market is further segmented into 
Chemotherapeutic, mAbs/Targeted Therapies, and Immunotherapeutic. Due to availability of variety of 
chemotherapeutic agent in the market chemotherapeutic drugs are expected to hold the higher share in 
blood cancer drugs market. Moreover, their effectiveness for the treatment of blood cancer and 
increasing number of cancer patients globally has garnered more demand for chemotherapeutic drugs 
throughout the world.
The leading companies operating in this industry include Johnson & Johnson Inc., Amgen Inc., Bayer 
AG., Pfizer, Inc., AbbVie Inc., Roche Holding AG., Celgene Corporation, AstraZeneca, Novartis AG, 
GlaxoSmithKline PLC, Merck & Co., Inc., and Eli Lily & Co. among others.
 
Key Findings from the study suggest blood cancer drugs in the market are much innovative and 
manufacturers are progressively concentrating on innovation of combination drugs. Companies are in a 
stage of development of new drugs in order to provide novel treatments for blood cancer. The 
immunotherapy segment is anticipated to grow at a high growth rate over the forecast period. The growth 
of this segment is primarily driven by increased awareness for its use as an alternative and effective 
treatment for blood cancer.                                                                       
                                                                   Browse Complete Report
Copyright © Polaris Market Research & Consulting LLP 2018. All Rights Reserved 4
Blood Cancer Drugs Market Size
Request for TOC
Copyright © Polaris Market Research & Consulting LLP 2018. All Rights Reserved 5
 Blood Cancer Drugs Market Study – Engagement Options
Buy Now – Click Here!
Buy now & have immediate access to premium insights
Purchase Report Sections – Click Here!
Regional analysis
Segmentation analysis
 Industry outlook
Competitive landscape
Speak To Analyst – Click Here!
Get your doubts clear
Schedule a call with our analyst before making any decision
Request For Sample Pages – Click Here!
Get free sample pages 
Understand report structure
Unmask data for validation
Copyright © Polaris Market Research & Consulting LLP 2018. All Rights Reserved 6
About Us
Polaris Market Research is a global market research and consulting company. The company 
specializes in providing exceptional market intelligence and in-depth business research services 
for our clientele spread across different enterprises. We at Polaris are obliged to e present across 
the industries of healthcare, technology, semi-conductors and chemicals among various other 
industries present around the world. 
We strive to provide our customers with updated information on innovative technologies, high 
growth markets, emerging business environments and latest business-centric applications, 
thereby helping them always to make informed decisions and leverage new opportunities. Adept 
with a highly competent, experienced and extremely qualified team of experts comprising SMEs, 
analysts and consultants, we at Polaris endeavor to deliver value-added business solutions to our 
customers.
 
Web: www.polarismarketresearch.com
Official Blog: http://polarismarketresearch.blogspot.com
Copyright © Polaris Market Research & Consulting LLP 2018. All Rights Reserved 7
Thank You!
Contact Us :
Polaris Market Research
30 Wall Street
8th Floor, 
New York City, NY 10005,
United States
E mail Id: [email protected]
Phone: +1-646-568-9980